Antifactor xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin

Pharmacotherapy

Volumn 32, Issue 6, 2012, Pages 546-558

  Vandiver, Jeremy W ^a   Vondracek, Thomas G ^a  

^a Exempla Saint Joseph Hospital   (United States)

Author keywords

Activated partial thromboplastin time; Anti Xa levels; Antifactor Xa levels; APTT; Heparin; Unfractionated heparin monitoring

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN; PROTAMINE;

ABSENCE OF SIDE EFFECTS; BLEEDING; BLOOD SAMPLING; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SAFETY; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; PARTIAL THROMBOPLASTIN TIME; PROCESS OPTIMIZATION; PROTEIN DETERMINATION; REVIEW; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FACTOR XA; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME;

EID: 84864614235     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2011.01049.x     Document Type: Review

References (56)

1. Anand S, Ginsberg JS, Kearon C, et al. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996;156:1677-81
2. Anand SS, Bates S, Ginsberg JS, et al. Recurrent venous thrombosis and heparin therapy. An evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999;159:2029-32
3. Hirsh J, Raschke R, Warkentin T, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108:258S-75S
4. Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on Laboratory monitoring of anticoagulant therapy. Arch Pathol Lab Med 1998;122:782-98
5. Hirsh J, Warkentin T, Shaughnessy S, et al. Heparin and lowmolecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S
6. Hirsh J, Raschke R. Heparin and low-molecular weight heparin: The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 2004;126:188S-203S
7. Rosenberg AF, Zumberg M, Taylor L, LeClaire A, Harris N. The use of anti-Xa assay to monitor intravenous unfractionated heparin therapy. Journal of Pharmacy Practice 2010;23:210-6
8. Kitchens CS. To bleed or not to bleed? Is that the question for the PTT? J Thromb Haemost 2005;3:2607-11
9. Rapaport SI. The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost 2004;2:2250-2
10. Eikelboom JW, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost 2006;96:547-52
11. Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287:324-7
12. Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977;49:171-84
13. Decousus HA, Croze M, Levi FA, et al. Circadian changes in anticoagulant effect of heparin infused at a constant rate. Br Med Journal 1985;290:341-4
14. Scully MF, Decousus HA, Ellis V, et al. Measurement of heparin in plasma: Influence of inter-subject and circadian variability in heparin sensitivity according to method. Thromb Res 1987;46:447-55
15. Krulder JW, de Boer A, van den Besselaar AM, et al. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers. Thromb Haemost 1992;68:30-2
16. Payne S, Mackinnon K, Keeney M, Morrow B, Kovacs MJ. Effect of 3.2% vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low-molecular weight heparin. Clin Lab Haematol 2003;25(30):317-9
17. Lehman CM, Frank EL. Laboratory monitoring of heparin therapy: Partial thromboplastin time or anti-Xa assay? Lab Medicine 2009;40:47-51
18. Diagnostica Stago. STA rotachrom heparin [package insert]. Parsippany, NJ: 2009
19. Kitchen S, Preston FE. The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays. Thromb Haemost 1996;75:734-9
20. Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992;152:1589-95
21. Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Arch Intern Med 1997;157:2475-9
22. Brill-Edwards P, Ginsberg J, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993;119:104-9
23. Rosborough TK. Comparing different lots of activated partial thromboplastin time reagent: Analysis of two methods. Am J Clin Pathol 1998;110:173-7
24. Volles DF, Ancell CJ, Michael KA, Mullins DM, Humphries JE. Establishing an institution-specific therapeutic range for heparin. Am J Health-Syst Pharm 1998;55:2002-6
25. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001;161:385-91
26. Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma heparin concentration. Pharmacotherapy 1999;19:922-31
27. Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003;138:720-3
28. Reed SV, Haddon ME, Denson KWE. An attempt to standardize the aPTT for heparin monitoring, using the P.T. ISI/INR system of calibration. Results of a 13 centre study. Thromb Res 1994;74:515-22
29. Van der Velde EA, Poller L. The aPTT monitoring of heparin -The IST/ICSH collaborative study. Thromb Haemost 1995;73:73-81
30. Van den Besselaar AMHP, Neuteboom J, Meeuwisse-Braun J, Bertina RM. Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: Usefulness for monitoring heparin therapy. Clin Chem 1997;43:1215-22
31. Van den Besselaar AM, meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: Relationships between the activated partial thromboplastin time and heparin assays based on exvivo heparin samples. Thromb Haemost 1990;63:16-23
32. Kapke GF, Feld RD, Witte DL, Owen WG. Esterolytic method for determination of heparin in plasma. Clin Chem 1981;27:526-9
33. Harenberg J. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins. J Mal Vasc 1987;12(Suppl B):68-70
34. Van den Besselaar AMHP, Sturk A, Reijnierse GLA. Monitoring of unfractionated heparin with the activated partial thromboplastin time: Determination of therapeutic ranges. Thromb Res 2002;107:235-40
35. Cuker A, Ptashkin B, Konkle A, et al. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time. J Thromb Haem 2008;7:80-6
36. Smythe MA, Mattson JC, Koerber JM. The heparin anti-Xa therapeutic Range: Are we there yet? (Editorial). Chest 2002;121:303-4
37. Camilleri JF, Bonnet JL, Bouvier JL, et al. Intravenous thrombolysis in myocardial infarction. Influence of the quality of the anticoagulation on the early recurrence rate of angina or infarction. Arch Mal Coeur Vaiss 1988;81(9):1037-41
38. Holm HA, Abildgaard U, Kalvenes S, et al. The antithrombotic effect of heparin in deep venous thrombosis: Relation to four heparin assays. Acta Med Scand 1984;216:287-93
39. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14
40. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: A randomized controlled trial. Ann Intern Med 1993;119:874-81
41. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8
42. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989;320(6):352-7
43. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction. Circulation 1996;93:870-8
44. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994;154:49-56
45. Rosborough TK. Monitoring unfractionated heparin therapy with antifactor Xa activity results in fewer monitoring tests and dosage changes than monitoring with activated partial thromboplastin time. Pharmacotherapy 1999;19:760-6
46. Rosborough TK, Shepherd MF. Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight. Pharmacotherapy 2004;24:713-9
47. Smith ML, Wheeler KE. Weight-based heparin protocol using antifactor Xa monitoring. Am J Health-Syst Pharm 2010;67:371-4
48. Miller AE, Montague D, Rogers JE, Sanghvi S, Whinna HC, Krumnacher H. Substitution of a heparin correlation value for activated partial thromboplastin time in heparin nomograms. Am J Health-Syst Pharm 2011;68:893-8
49. Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Ann Pharmacother 2011;45:861-8
50. Holm HA, Abildgaard U, Kalvenes S. Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 1985;53:278-81
51. Niewenhuis HK, Albada J, Banga JD, et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular heparin. Blood 1991;78:2337-43
52. Smythe M, Koerber BS. Heparin monitoring: The confusion continues. Pharmacotherapy 1999;19:1240-2
53. Taylor CT, Petros WP, Ortel TL. Two instruments to determine activated partial thromboplastin time: Implications for heparin monitoring. Pharmacotherapy 1999;19:383-7
54. Kitchen S, Theaker J, Preston FE. Monitoring unfractionated heparin therapy: Relationship between eight anti-Xa assays and a protamine titration assay. Blood Coagul Fibrinolysis 2000;11:137-44
55. Kovacs MJ, Keeney M, Mackinnon K, Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haem 1999;21:55-60
56. Valenstein PN, Walsh MK, Meier F. Heparin monitoring and patient safety: A College of American Pathology Q-probes study of 3,431 patients at 140 institutions. Arch Pathol Lab Med 2004;128:397-402.